{
    "nctId": "NCT03908749",
    "briefTitle": "A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2",
    "officialTitle": "A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2 Positive Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female patients .\n2. Confirmed by pathological examination of breast cancer patients with positive her-2 expression\n3. The researchers determined that the standard neoadjuvant regimen was ineffective in the treatment of patients with locally advanced her-2 positive breast cancer or that the standard neoadjuvant regimen was not applicable.\n4. Patients should be voluntary to the trial and provide with signed informed consent\n5. The researchers believe patients can benefit from the study.\n\nExclusion Criteria:\n\n1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Pyrotinib maleate tablets or its accessories\n2. Pregnant or lactating women\n3. Patients with Pyrotinib maleate tablets contraindications\n4. Patients of doctors considered unsuitable for the trial",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}